

## 510(k) Summary

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of the Safe Medical Devices Act of 1990 and 21 C.F.R. §807.92.

1. The submitter of this premarket notification is:

APR 30 2010

Andreas Suchi  
Philips Medizin Systeme Boeblingen GmbH  
Hewlett-Packard-Str. 2  
D-71034 Boeblingen, Germany  
Tel: ++49 7031 463-1291 Fax: ++49 7031 463-2442  
e-mail: andreas.suchi@philips.com

This summary was prepared on April 1, 2010.

2. The names of the devices are the Philips MP2, X2, MP5, MP5T, MP20, MP30, MP40, MP50, MP60, MP70, MP75, MP80, and MP90 IntelliVue patient monitors  
Classification names are as follows:

Device Panel	Classification	ProCode	Description
Cardiovascular Devices	\$870.1025, II	DSI	Detector and alarm, arrhythmia
	\$870.1025, II	MLD	Monitor, ST Segment with Alarm
	\$870.1025, II	MHX	Monitor, Physiological, Patient (with arrhythmia detection or alarms)
	\$870.1100, II	DSJ	Alarm, Blood Pressure
	\$870.1110, II	DSK	Computer, Blood Pressure
	\$870.1130, II	DXN	System, Measurement, Blood-Pressure, Non-Invasive
	\$870.1435, II	DXG	Computer, Diagnostic, Pre-Programmed, Single-Function
	\$870.1915, II	KRB	Probe, Thermodilution
	\$870.2060, II	DRQ	Amplifier and Signal Conditioner, Transducer Signal
	\$870.2300, II	DRT	Monitor, Cardiac (incl. Cardiotachometer & Rate Alarm)
	\$870.2340, II	DPS	Electrocardiograph
	\$870.2340, II	MLC	Monitor, ST Segment
	\$870.2350, II	DRW	Electrocardiograph, Lead Switching Adapter
	\$870.2370, II	KRC	Tester, Electrode, Surface, Electrocardiograph
	\$870.2600, I	DRJ	System, Signal Isolation
	\$870.2700, II	DQA	Oximeter
	\$870.2770, II	DSB	Plethysmograph, Impedance
	\$870.2800, II	DSH	Recorder, Magnetic tape, Medical
	\$870.2810, I	DSF	Recorder, Paper Chart
	\$870.2850, II	DRS	Extravascular Blood Pressure Transducer
	\$870.2900, I	DSA	Cable, Transducer and Electrode, incl. Patient Connector

Device Panel	Classification	ProCode	Description
	-	MSX	System, Network and Communication, Physiological Monitors
	\$870.2910, II	DRG	Transmitters and Receivers, Physiological Signal, Radiofrequency
Anesthesiology Devices	\$868.1400, II	CCK	Analyzer, Gas, Carbon Dioxide, Gaseous-Phase
	\$868.1500, II	CBQ	Analyzer, Gas, Enflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHO	Analyzer, Gas, Desflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHP	Analyzer, Gas, Sevoflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1500, II	NHQ	Analyzer, Gas, Isoflurane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1620, II	CBS	Analyzer, Gas, Halothane, Gaseous-Phase (Anesthetic Concentration)
	\$868.1700, II	CBR	Analyzer, Gas, Nitrous Oxide, Gaseous-Phase (Anesthetic Concentration)
	\$868.1720, II	CCL	Analyzer, Gas, Oxygen, Gaseous-Phase
	\$868.1880, II	BZC	Data calculator Pulmonary-function
	\$868.2375, II	BZQ	Monitor, Breathing Frequency
	\$868.2480, II	LKD	Monitor, Carbon Dioxide, Cutaneous
	\$868.2500, II	KLK	Monitor, Oxygen, Cutaneous, for Infant not under Gas Anesthesia
General Hospital and Personal Use Devices	\$880.2910, II	FLL	Thermometer, Electronic, Clinical
Neurological Devices	\$882.1400, II	GWR	Electroencephalograph
	\$882.1420, I	GWS	Analyzer, Spectrum, Electroencephalogram Signal

3. The modified devices are substantially equivalent to previously cleared Philips IntelliVue patient monitors marketed pursuant to K013199, K031481, K032858, K040304, K050762, K053522, K062392, K71426, K081793, K082633, K083517, and K091927 .
4. The modification is the introduction of software revision H.00 for the entire IntelliVue patient monitors family, models MP2, X2, MP5, MP5T, MP20, MP30, MP40, MP50, MP60, MP70, MP80, and MP90.  
Additionally a new model IntelliVue MP75 is introduced.

5. The modified devices have the same intended use as the legally marketed predicate devices. The Philips MP2, X2, MP5, MP5T, MP20, MP30, MP40, MP50, MP60, MP70, MP75, MP80, and MP90 IntelliVue patient monitors are intended for monitoring and recording of and to generate alarms for, multiple physiological parameters of adults, pediatrics and neonates in hospital environments. The MP2, X2, MP5, MP5T, MP20, MP30, MP40, and MP50 are additionally intended for use in transport situations within hospital environments. The MP2, X2 and MP5 are also intended for use during patient transport outside of a hospital environment. The monitors are not intended for home use. They are intended for use by health care professionals.
6. The modified devices have the same technological characteristics as the legally marketed predicate device.
7. Verification, validation, and testing activities establish the performance, functionality, and reliability characteristics of the modified devices with respect to the predicate. Testing involved system level and regression tests as well as testing from the hazard analysis. Pass/Fail criteria were based on the specifications cleared for the predicate devices and test results showed substantial equivalence. The results demonstrate that the Philips IntelliVue patient monitors meet all reliability requirements and performance claims.



Food and Drug Administration  
10903 New Hampshire Avenue  
Document Control Room W-066-0609  
Silver Spring, MD 20993-0002

APR 30 2010

Philips Medizin Systeme Boeblingen GmbH  
c/o Mr. Andreas Suchi  
Senior Regulatory Affairs Engineer  
Hewlett-Packard Str. 2  
Boeblingen  
GERMANY 71034

Re: K100939

Trade/Device Name: Philips MP2, X2, MP5, MP5T, MP20, MP30, MP40, MP50, MP60,  
MP70, MP75, MP80, and MP90 IntelliVue patient monitors, Release H.00

Regulatory Number: 21 CFR 870.1025

Regulation Name: Patient Physiological Monitor (with arrhythmia detection or alarms)

Regulatory Class: II (two)

Product Code: 74 MHX

Dated: April 1, 2010

Received: April 5, 2010

Dear Mr. Suchi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "B. D. Zuckerman", with a stylized flourish at the end.

Bram D. Zuckerman, M.D.

Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): \_\_\_\_\_


Device Name: Philips MP2, X2, MP5, MP5T, MP20, MP30, MP40, MP50, MP60, MP70, MP75, MP80, and MP90 IntelliVue patient monitors, Release H.00.

Indications for Use: Indicated for use by health care professionals whenever there is a need for monitoring the physiological parameters of patients.

Prescription Use \_\_\_\_\_ Yes \_\_\_\_\_ AND/OR Over-The-Counter Use \_\_\_\_\_ No \_\_\_\_\_  
(Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)



(Division Sign-Off)  
Division of Cardiovascular Devices

510(k) Number K100939